The Bull Rankings scorecard — our quality-growth score is 46.2 / 100, built from three pillars scored 0–100: Quality 53, Growth 42, Value 44 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free cash flow shrinking about 3% next year, then recovering toward 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Albertsons eked out 3.5% revenue growth in the quarter ended 2026-02-28 while sporting a 13.5% return on equity and a razor-thin 0.3% profit margin. Our model gives it a 46.2/100 quality-growth score, with the Quality pillar at 53 and Growth at 42. The weakest pillar is Growth, yet the stock is priced as if the company can deliver free-cash-flow growth of roughly -3% a year (in year one, recovering toward 3% a year by year ten). That’s a bet the market is making on stability, not expansion.
What the business actually is
Albertsons sells groceries, general merchandise, health and beauty care, pharmacy services, vaccines, fuel, and coffee-shop drinks through a sprawling portfolio of banners that anchor neighborhoods from coast to coast. The pharmacy and fuel segments are the quiet growth engines: prescriptions and immunizations drive repeat traffic, while fuel margins add low-friction cash at the pump. The in-store coffee shops and loyalty programs turn a weekly shopping trip into a branded experience. These are not luxuries; they’re sticky services that lock in customers and raise the average ticket.
Why it can (or can't) keep compounding
The company’s 13.5% return on equity in the quarter ended 2026-02-28 shows capital is still working, but the 0.3% profit margin tells a different story: every dollar of sales is barely profitable. Our model flags “Buying back stock” as a signal, yet the debt-to-equity ratio stands at 9.74, a leverage load that limits future buybacks without cash flow relief. The moat isn’t scale alone; it’s the density of stores in metro areas where competitors would need years to replicate the shelf space, pharmacy licenses, and fuel supply agreements. Still, that moat erodes if pricing power stays muted and wage inflation keeps pressing margins.
The valuation question
The P/E sits at 76.4 times trailing earnings in the quarter ended 2026-02-28, while our reverse DCF says the price assumes free cash flow shrinking roughly -3% annually (in year one, recovering toward 3% a year by year ten). Against that, revenue grew just 3.5% year over year. The market is paying up for stability, not growth. The stock’s 52-week range of $10.86 to $20 shows how binary the view has become: either the pharmacy and fuel flyers keep cash flowing, or the leverage drags returns into negative territory. The bulls are betting on the former; the bears are pricing the latter.
The bear case
Short interest is in play again this month, and simplywall.st notes the company missed earnings and cut its full-year EPS outlook. With a 76.4 P/E and debt-to-equity at 9.74, the math only works if margins expand or revenue accelerates. Neither is guaranteed. The weakest pillar in our model—Growth at 42—already flags the risk that the company can’t outgrow its cost base. If the next quarter posts another miss or the pharmacy reimbursement squeeze tightens, the -3% implied free-cash-flow decay could look generous.
What would change our mind
First, if the profit margin climbs above 1% in a single quarter, the valuation starts to look less heroic. Second, if the company pares debt-to-equity below 8 while maintaining buybacks, the Quality pillar would firm up. Third, any acceleration in revenue growth above 5% year over year would flip the Growth pillar from weak to credible. Until then, the stock is a bet on stability, not compounding.